Cetuximab (Erbitux®) is a chimeric (mouse/human) monoclonal antibody, specific for EGFR (epidermal growth factor receptor), used for treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab inhibits the receptor-associated tyrosine kinase, thus blocking the intracellular signalling pathway that results in cell proliferation.

We have considerable experience in the analysis of different variants of Erbitux originators and biosimilars.

To support the analytical development of Erbitux biosimilars or biobetters, Protagen has set up an analysis program in accordance with ICH Q6B guidelines, including method setup, validation of customer-specific methods, and release testing. This package includes protein quantification, characterizing the protein primary structure, analysis of N- glycosylation and protein modifications.

Specific BioAssay provided by a strategic partner:

  • Target: EGF-R Assay type: Proliferation Assay, statistical analysis by PLA


Your contact for Cetuximab at Protagen Protein Services GmbH

Martin-Blueggel 150x100px

Martin Blüggel

Chief Executive Officer (CEO)
Our business development team will be happy to assist you with your project.

Phone: +49 (0) 231 9742-6100
Email: salesproteinservices@ProtagenProteinServices.com